P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR. (23rd June 2022) - Mascarenhas, J.; Harrison, C. N.; Kiladjian, J.-J.; Komrokji, R. S.; Koschmieder, S.; Vannucchi, A. M.; Berry, T.; Redding, D.; Sherman, L.; Dougherty, S.; Peng, L.; Sun, L.; et al.